Incidence of severe hepatotoxicity related to antiretroviral therapy in HIV/HCV coinfected patients

Journal Article

Introduction. Hepatotoxicity is a concern in HIV/hepatitis C virus (HCV) coinfected patients due to their underlying liver disease. This study assessed the incidence of hepatotoxicity in HIV/HCV co-infected patients in two outpatient infectious diseases clinics. Methods. HIV/HCV co-infected adults were included in this retrospective study if they were PI or NNRTI naïve at their first clinic visit and were initiated on an NNRTI- and/or PI-based antiretroviral regimen. Patients were excluded if they had active or chronic hepatitis B virus (HBV). The primary objective was to determine the overall incidence of severe hepatotoxicity. Results. Fifty-six of the 544 patients identified met inclusion criteria. The incidence of severe hepatotoxicity was 10.7% (6/56 patients). Severe hepatotoxicity occurred with efavirenz (N=2), nevirapine (N=1), indinavir (N=1), nelfinavir (N=1), and saquinavir/ritonavir (N=1). Conclusion. The incidence of severe hepatotoxicity appears to be low in this retrospective analysis of HIV/HCV co-infected patients receiving a PI-and/or NNRTI-based regimen. © 2010 Emily L. Heil et al.

Full Text

Duke Authors

Cited Authors

  • Heil, EL; Townsend, ML; Shipp, K; Clarke, A; Johnson, MD

Published Date

  • 2010

Published In

Volume / Issue

  • 2010 /

PubMed ID

  • 21490905

International Standard Serial Number (ISSN)

  • 2090-1240

Digital Object Identifier (DOI)

  • 10.1155/2010/856542